{"id":"inolimomab-leukotac","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Immunosuppression-related complications"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Inolimomab targets CD25, the alpha subunit of the IL-2 receptor expressed on activated T lymphocytes. By blocking IL-2 signaling through this receptor, the drug inhibits T cell proliferation and activation, reducing pathogenic immune responses. This mechanism is intended to control inflammatory and autoimmune conditions driven by overactive T cell responses.","oneSentence":"Inolimomab is a monoclonal antibody that blocks the IL-2 receptor alpha chain (CD25) on T cells to suppress excessive immune activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:19.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Graft-versus-host disease (GVHD)"}]},"trialDetails":[{"nctId":"NCT05047328","phase":"","title":"Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease","status":"AVAILABLE","sponsor":"ElsaLys Biotech","startDate":"","conditions":"Steroid Resistant Acute Graft Versus Host Disease","enrollment":""},{"nctId":"NCT04289103","phase":"PHASE3","title":"Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD","status":"UNKNOWN","sponsor":"ElsaLys Biotech","startDate":"2021-10","conditions":"Steroid Refractory GVHD","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Inolimomab (Leukotac)","genericName":"Inolimomab (Leukotac)","companyName":"ElsaLys Biotech","companyId":"elsalys-biotech","modality":"Biologic","firstApprovalDate":"","aiSummary":"Inolimomab is a monoclonal antibody that blocks the IL-2 receptor alpha chain (CD25) on T cells to suppress excessive immune activation. Used for Graft-versus-host disease (GVHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}